老虎證券

BRIEF-Merck Says FDA PDUFA Date For Subcutaneous Pembrolizumab Set For Sept 23

Reuters
2025/03/27
BRIEF-Merck Says FDA PDUFA Date For Subcutaneous Pembrolizumab Set For Sept 23

March 27 (Reuters) - Merck & Co Inc MRK.N:

  • MERCK: INVESTIGATIONAL SUBCUTANEOUS PEMBROLIZUMAB WITH BERAHYALURONIDASE ALFA SHOWS NONINFERIOR PHARMACOKINETICS VERSUS IV KEYTRUDA IN 3475A-D77 TRIAL

  • MERCK: APPLICATIONS FOR SUBCUTANEOUS PEMBROLIZUMAB ARE UNDER REVIEW IN U.S. & EUROPE

  • MERCK: FDA HAS SET PDUFA DATE OF SEPT 23

  • MERCK EXEC SAYS WILL LAUNCH SUBCUTANEOUS KEYTRUDA AT RISK IF HALOZYME PATENT DISPUTE NOT RESOLVED YET - INTERVIEW

  • MERCK EXEC SAYS HOPES TO LAUNCH SUBCUTANEOUS KEYTRUDA ON OCT 1, SEES PEAK ADOPTION ABOUT 18-24 MONTHS AFTER APPROVAL - INTERVIEW

Further company coverage: MRK.N

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10